Astellas Pharma (4503) · InitiativeAchieved
Termination of the Technology License Agreement with Vical for a Prophylactic Vaccine Against Cytomegalovirus Viremia
First written in FY2019-Q2. 1 of 1 entries say "Achieved", first in FY2019-Q2. Latest entry: FY2019-Q2.
1entries
1years
0from disclosures
How it moved
Same theme, other companies
Termination of Technology Licensing Agreement with Vical for Cytomegalovirus Prophylactic VaccineA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first